At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 6 enrolled
Drug / intervention
Tasignadrug
Likely dose
Tasigna 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas
In Brief
A Early Phase 1 clinical trial evaluating Tasigna for Neurofibromatosis and 2 related conditions. Completed, enrolled 6 participants across 1 site.
Detailed Summary
The purpose of this Pilot Study is to determine if NF1 patients with plexiform neurofibromas treated with Tasgina® respond to therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeurofibromatosis, NF1, Neurofibromas
CountriesUnited States
CollaboratorsNovartis
Timeline
Early Ph 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2011
First PostedJan 2011
Primary CompletionJul 2016
Study CompletionOct 2016
TodayJul 2026
First PostedJan 12, 2011
Enrollment StartJan 1, 2011
Primary CompletionJul 1, 2016
Study CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 15.5 years ago
Interventions
Tasignadrug
Following enrollment each subject will initially receive Tasigna orally at 200 mg twice daily for two weeks. If tolerated, the dose will be increased to 300 mg twice daily after a minimum of two weeks and will be increase to a maximum dose of 400mg twice daily after an additional two weeks if tolerated.